24111
document
Clinical trials of intrasplenic arterial infusion of interleukin-2 ( IS-IL-2 ) to patients with advanced cancer . We tried a infusion of interleukin-2 ( IL-2 ) of a relatively low dose via an intrasplenic arterial catheter connected to a chronometric infusion ( IS-IL-2 ) . Eighteen patients of colorectal cancer with metastases to the liver or lung or of unresectable hepatoma received a 24 hour continuous infusion with low dose recombinant of IL-2 ( mainly 8 x 10 ( 5 ) JRU/day ) for 25-40 days . All patients tolerated this protocol of the therapy and the main toxic effects were fever and general fatigue . Such serious toxicity as previously reported by high dose IL-2 therapy was not observed . Data of hepatic and renal functions were normal . IS-IL-2 therapy induced a high incidence of eosinophilia ( 12/18 ) and thrombocythemia ( 12/18 ) . Peripheral natural killer ( NK ) and LAK activities were augmented in all patients and total white blood cell counts were increased during IS-IL-2 therapy . An increase in IL-2 receptor expression of peripheral blood mononuclear cells and significant rises in numbers of Leu11 ( CD16 ) + , OKM1 ( CD11 ) + and OKIa1 ( HLA-DR ) + were observed . Of 18 patients 12 were evaluable for their response to therapy . Partial response ( PR ) was observed in one unresectable hepatoma and 11 demonstrated no change ( NC ) or progressive disease ( PD ) . Six patients were not evaluable because of additional therapy ( 3 cases ) or decreasing tumor cell markers having no measurable lesions ( 3 cases ) . Three patients of colorectal cancer from an unresectable group were presumed to have micrometastases to the liver as suggested by an elevated serum CEA level . After receiving IS-IL-2 therapy they demonstrated a decrease in the serum CEA level for more than 3 years after treatment . ( ABSTRACT TRUNCATED AT 250 WORDS )
24112
Intervention_Pharmacological
interleukin-2 ( IS-IL-2 )
24113
Intervention_Pharmacological
low dose recombinant of IL-2
24114
Outcome_Other
tolerated
24115
Outcome_Adverse-effects
toxic effects
24116
Outcome_Adverse-effects
fever
24117
Outcome_Adverse-effects
general fatigue
24118
Outcome_Adverse-effects
toxicity
24119
Outcome_Physical
hepatic and renal functions
24120
Outcome_Adverse-effects
eosinophilia
24121
Outcome_Physical
( 12/18 )
24122
Outcome_Adverse-effects
thrombocythemia
24123
Outcome_Physical
Peripheral natural killer ( NK ) and LAK activities
24124
Outcome_Physical
total white blood cell counts
24125
Outcome_Physical
IL-2 receptor expression of peripheral blood mononuclear cells and significant rises in numbers of Leu11 ( CD16 ) + , OKM1 ( CD11 ) + and OKIa1 ( HLA-DR ) +
24126
Outcome_Physical
unresectable hepatoma
24127
Outcome_Physical
no change ( NC ) or progressive disease ( PD )
24128
Participant_Condition
patients with advanced cancer .
24129
Participant_Condition
Eighteen patients of colorectal cancer with metastases to the liver or lung or of unresectable hepatoma
24130
Participant_Condition
Of 18 patients 12 were evaluable for their response to therapy .